-
Je něco špatně v tomto záznamu ?
Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma: The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial
S. Daw, A. Claviez, L. Kurch, D. Stoevesandt, A. Attarbaschi, W. Balwierz, A. Beishuizen, M. Cepelova, F. Ceppi, A. Fernandez-Teijeiro, A. Fosså, TW. Georgi, LL. Hjalgrim, A. Hraskova, T. Leblanc, M. Mascarin, J. Pears, J. Landman-Parker, T....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, klinické zkoušky, fáze III, multicentrická studie, komentáře
- MeSH
- autologní transplantace MeSH
- dítě MeSH
- etoposid terapeutické užití aplikace a dávkování MeSH
- Hodgkinova nemoc * terapie farmakoterapie patologie MeSH
- lidé MeSH
- lokální recidiva nádoru MeSH
- mladiství MeSH
- pozitronová emisní tomografie MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- transplantace hematopoetických kmenových buněk MeSH
- záchranná terapie * MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- komentáře MeSH
- multicentrická studie MeSH
IMPORTANCE: The current standard-of-care salvage therapy in relapsed/refractory classic Hodgkin lymphoma (cHL) includes consolidation high-dose chemotherapy (HDCT)/autologous stem cell transplant (aSCT). OBJECTIVE: To investigate whether presalvage risk factors and fludeoxyglucose-18 (FDG) positron emission tomography (PET) response to reinduction chemotherapy can guide escalation or de-escalation between HDCT/aSCT or transplant-free consolidation with radiotherapy to minimize toxic effects while maintaining high cure rates. DESIGN, SETTING, AND PARTICIPANTS: EuroNet-PHL-R1 was a nonrandomized clinical trial that enrolled patients younger than 18 years with first relapsed/refractory cHL across 68 sites in 13 countries in Europe between January 2007 and January 2013. Data were analyzed between September 2022 and July 2024. INTERVENTION: Reinduction chemotherapy consisted of alternating IEP (ifosfamide, etoposide, prednisolone) and ABVD (adriamycin, bleomycin, vinblastine, dacarbazine). Patients with low-risk disease (late relapse after 2 cycles of first-line chemotherapy and any relapse with an adequate response after 1 IEP/ABVD defined as complete metabolic response on FDG-PET and at least 50% volume reduction) received a second IEP/ABVD cycle and radiotherapy (RT) to all sites involved at relapse. Patients with high-risk disease (all primary progressions and relapses with inadequate response after 1 IEP/ABVD cycle) received a second IEP/ABVD cycle plus HDCT/aSCT with or without RT. MAIN OUTCOMES AND MEASURES: The primary end point was 5-year event-free survival. Secondary end points were overall survival (OS) and progression-free survival (PFS). PFS was identical to event-free survival because no secondary cancers were observed. PFS data alone are presented for simplicity. RESULTS: Of 118 patients analyzed, 58 (49.2%) were female, and the median (IQR) age was 16.3 (14.5-17.6) years. The median (IQR) follow-up was 67.5 (58.5-77.0) months. The overall 5-year PFS was 71.3% (95% CI, 63.5%-80.1%), and OS was 82.7% (95% CI, 75.8%-90.1%). For patients in the low-risk group (n = 59), 41 received nontransplant salvage with a 5-year PFS of 89.7% (95% CI, 80.7%-99.8%) and OS of 97.4% (95% CI, 92.6%-100%). In contrast, 18 received HDCT/aSCT off protocol, with a 5-year PFS of 88.9% (95% CI, 75.5%-100%) and OS of 100%. All 59 patients with high-risk disease received HDCT/aSCT (and 23 received post-HDCT/aSCT RT) with a 5-year PFS of 53.3% (95% CI, 41.8%-67.9%) and OS of 66.5% (95% CI, 54.9%-80.5%). CONCLUSION AND RELEVANCE: In this nonrandomized clinical trial, FDG-PET response-guided salvage in relapsed cHL may identify patients in whom transplant-free salvage achieves excellent outcomes. HDCT/aSCT may be reserved for primary progression and relapsed cHL with inadequate response. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00433459.
Children's Health Ireland Crumlin Dublin Ireland
Department of Cellular Pathology University College Hospital London London United Kingdom
Department of Nuclear Medicine University Hospital Leipzig Leipzig Germany
Department of Pediatrics University Hospital Magdeburg Magdeburg Germany
Department of Radiology University Hospital Halle Germany
Department of Radiooncology Allgemeines Krankenhaus Wien Medical University Vienna Vienna Austria
Department of Radiooncology University Hospital Halle Germany
Disease and Comenius University Bratislava Bratislava Slovakia
Hôpital Robert Debré Service d'Hématologie Pédiatrique and Université Paris Cité Paris Paris France
Institute for Medical Informatics Statistics and Epidemiology University of Leipzig Leipzig Germany
Jagiellonian University Medical College Institute of Pediatrics Krakow Poland
Medical Faculty of the Martin Luther University Halle Wittenberg Halle Germany
Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands
Universidad de Sevilla Hospital Universitario Virgen Macarena Sevilla Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009711
- 003
- CZ-PrNML
- 005
- 20250429135349.0
- 007
- ta
- 008
- 250415s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1001/jamaoncol.2024.5636 $2 doi
- 035 __
- $a (PubMed)39745682
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Daw, Stephen $u Pediatric Division, Children and Young People's Cancer Services, University College London Hospital, London, United Kingdom
- 245 10
- $a Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma: The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial / $c S. Daw, A. Claviez, L. Kurch, D. Stoevesandt, A. Attarbaschi, W. Balwierz, A. Beishuizen, M. Cepelova, F. Ceppi, A. Fernandez-Teijeiro, A. Fosså, TW. Georgi, LL. Hjalgrim, A. Hraskova, T. Leblanc, M. Mascarin, J. Pears, J. Landman-Parker, T. Prelog, W. Klapper, A. Ramsay, R. Kluge, K. Dieckmann, T. Pelz, D. Vordermark, D. Körholz, D. Hasenclever, C. Mauz-Körholz
- 520 9_
- $a IMPORTANCE: The current standard-of-care salvage therapy in relapsed/refractory classic Hodgkin lymphoma (cHL) includes consolidation high-dose chemotherapy (HDCT)/autologous stem cell transplant (aSCT). OBJECTIVE: To investigate whether presalvage risk factors and fludeoxyglucose-18 (FDG) positron emission tomography (PET) response to reinduction chemotherapy can guide escalation or de-escalation between HDCT/aSCT or transplant-free consolidation with radiotherapy to minimize toxic effects while maintaining high cure rates. DESIGN, SETTING, AND PARTICIPANTS: EuroNet-PHL-R1 was a nonrandomized clinical trial that enrolled patients younger than 18 years with first relapsed/refractory cHL across 68 sites in 13 countries in Europe between January 2007 and January 2013. Data were analyzed between September 2022 and July 2024. INTERVENTION: Reinduction chemotherapy consisted of alternating IEP (ifosfamide, etoposide, prednisolone) and ABVD (adriamycin, bleomycin, vinblastine, dacarbazine). Patients with low-risk disease (late relapse after 2 cycles of first-line chemotherapy and any relapse with an adequate response after 1 IEP/ABVD defined as complete metabolic response on FDG-PET and at least 50% volume reduction) received a second IEP/ABVD cycle and radiotherapy (RT) to all sites involved at relapse. Patients with high-risk disease (all primary progressions and relapses with inadequate response after 1 IEP/ABVD cycle) received a second IEP/ABVD cycle plus HDCT/aSCT with or without RT. MAIN OUTCOMES AND MEASURES: The primary end point was 5-year event-free survival. Secondary end points were overall survival (OS) and progression-free survival (PFS). PFS was identical to event-free survival because no secondary cancers were observed. PFS data alone are presented for simplicity. RESULTS: Of 118 patients analyzed, 58 (49.2%) were female, and the median (IQR) age was 16.3 (14.5-17.6) years. The median (IQR) follow-up was 67.5 (58.5-77.0) months. The overall 5-year PFS was 71.3% (95% CI, 63.5%-80.1%), and OS was 82.7% (95% CI, 75.8%-90.1%). For patients in the low-risk group (n = 59), 41 received nontransplant salvage with a 5-year PFS of 89.7% (95% CI, 80.7%-99.8%) and OS of 97.4% (95% CI, 92.6%-100%). In contrast, 18 received HDCT/aSCT off protocol, with a 5-year PFS of 88.9% (95% CI, 75.5%-100%) and OS of 100%. All 59 patients with high-risk disease received HDCT/aSCT (and 23 received post-HDCT/aSCT RT) with a 5-year PFS of 53.3% (95% CI, 41.8%-67.9%) and OS of 66.5% (95% CI, 54.9%-80.5%). CONCLUSION AND RELEVANCE: In this nonrandomized clinical trial, FDG-PET response-guided salvage in relapsed cHL may identify patients in whom transplant-free salvage achieves excellent outcomes. HDCT/aSCT may be reserved for primary progression and relapsed cHL with inadequate response. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00433459.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a Hodgkinova nemoc $x terapie $x farmakoterapie $x patologie $7 D006689
- 650 12
- $a záchranná terapie $7 D016879
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 _2
- $a lokální recidiva nádoru $7 D009364
- 650 _2
- $a autologní transplantace $7 D014182
- 650 _2
- $a pozitronová emisní tomografie $7 D049268
- 650 _2
- $a etoposid $x terapeutické užití $x aplikace a dávkování $7 D005047
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a komentáře $7 D016420
- 700 1_
- $a Claviez, Alexander $u Department of Pediatrics, University Hospital Magdeburg, Magdeburg, Germany
- 700 1_
- $a Kurch, Lars $u Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
- 700 1_
- $a Stoevesandt, Dietrich $u Department of Radiology, University Hospital Halle (Saale), Halle (Saale), Germany
- 700 1_
- $a Attarbaschi, Andishe $u Department of Paediatric Haematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, St Anna Children's Cancer Research Institute, Vienna, Austria
- 700 1_
- $a Balwierz, Walentyna $u Jagiellonian University Medical College, Institute of Pediatrics, Krakow, Poland
- 700 1_
- $a Beishuizen, Auke $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
- 700 1_
- $a Cepelova, Michaela $u Department of Paediatric Haematology and Oncology, University Hospital Motol and 2nd Medical Faculty of Charles University, Prague, Czech Republic
- 700 1_
- $a Ceppi, Francesco $u Division of Pediatrics, Department of Woman-Mother-Child, Pediatric Hematology-Oncology Unit, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland
- 700 1_
- $a Fernandez-Teijeiro, Ana $u Universidad de Sevilla, Hospital Universitario Virgen Macarena, Sevilla, Spain
- 700 1_
- $a Fosså, Alexander $u Oslo University Hospital, Department of Oncology, and KG Jebsen Centre for B-cell malignancies, University of Oslo, Oslo, Norway
- 700 1_
- $a Georgi, Thomas W $u Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
- 700 1_
- $a Hjalgrim, Lisa Lyngsie $u Department of Paediatrics and Adolescents Medicine, Rigshospitalet Copenhagen, The Juliane Marie Centre, Copenhagen, Denmark
- 700 1_
- $a Hraskova, Andrea $u Disease and Comenius University Bratislava, Bratislava, Slovakia
- 700 1_
- $a Leblanc, Thierry $u Hôpital Robert-Debré, Service d'Hématologie Pédiatrique and Université Paris-Cité Paris, Paris, France
- 700 1_
- $a Mascarin, Maurizio $u Department of Radiation Oncology, AYA Oncology and Pediatric Radiotherapy Unit, CRO Centro di Riferimento Oncologico, IRCCS, Aviano (PN), Italy
- 700 1_
- $a Pears, Jane $u Children's Health Ireland, Crumlin, Dublin, Ireland
- 700 1_
- $a Landman-Parker, Judith $u Department of Paediatric Oncology and Haematology, Hôpital Armand-Trousseau, Sorbonne Université, Paris, France
- 700 1_
- $a Prelog, Tomaž $u Department of Pediatric Hematology and Oncology, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Klapper, Wolfram $u Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Christian-Albrechts-Universität, Kiel, Germany
- 700 1_
- $a Ramsay, Alan $u Department of Cellular Pathology, University College Hospital London, London, United Kingdom
- 700 1_
- $a Kluge, Regine $u Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
- 700 1_
- $a Dieckmann, Karin $u Department of Radiooncology, Allgemeines Krankenhaus Wien, Medical University Vienna, Vienna, Austria
- 700 1_
- $a Pelz, Tanja $u Department of Radiooncology, University Hospital Halle (Saale), Halle (Saale), Germany
- 700 1_
- $a Vordermark, Dirk $u Department of Radiooncology, University Hospital Halle (Saale), Halle (Saale), Germany
- 700 1_
- $a Körholz, Dieter $u Department of Paediatric Haematology, Oncology and Immunodeficiency, University Hospital Justus-Liebig University Giessen, Giessen, Germany
- 700 1_
- $a Hasenclever, Dirk $u Institute for Medical Informatics, Statistics, and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany
- 700 1_
- $a Mauz-Körholz, Christine $u Department of Paediatric Haematology, Oncology and Immunodeficiency, University Hospital Justus-Liebig University Giessen, Giessen, Germany $u Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
- 773 0_
- $w MED00186178 $t JAMA oncology $x 2374-2445 $g Roč. 11, č. 3 (2025), s. 258-267
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39745682 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135345 $b ABA008
- 999 __
- $a ok $b bmc $g 2311216 $s 1246792
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 11 $c 3 $d 258-267 $e 20250301 $i 2374-2445 $m JAMA oncology $n JAMA Oncol $x MED00186178
- LZP __
- $a Pubmed-20250415
